$BFNH
BIOFORCE NANOSCIENCES HOLDINGS, INC. Stock $bfnh

$bfnh Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-Q Financial Statement

#000109181824000134 Filed on November 08, 2024

Income Statement

Concept	2024 Q4	2024 Q3
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin		$122.0K
YoY Change		7.4%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses		$122.0K
YoY Change		7.41%
Operating Profit		-$122.0K
YoY Change		7.41%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income		-$122.0K
YoY Change		7.4%
Income Tax
% Of Pretax Income
Net Earnings		-$122.0K
YoY Change		7.41%
Net Earnings / Revenue
Basic Earnings Per Share		$0.00
Diluted Earnings Per Share		$0.00
COMMON SHARES
Basic Shares Outstanding	29.27M shares	29.27M shares
Diluted Shares Outstanding		29.27M shares

Balance Sheet

Concept	2024 Q4	2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments		$1.640K
YoY Change		137.68%
Cash & Equivalents		$1.635K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets		$1.635K
YoY Change		138.34%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets		$0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets		$1.635K
Total Long-Term Assets		$0.00
Total Assets		$1.635K
YoY Change		138.34%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable		$6.260K
YoY Change		479.63%
Accrued Expenses		$1.914M
YoY Change		28.37%
Deferred Revenue
YoY Change
Short-Term Debt		$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities		$2.180M
YoY Change		27.83%
LONG-TERM LIABILITIES
Long-Term Debt		$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities		$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities		$2.180M
Total Long-Term Liabilities		$0.00
Total Liabilities		$2.180M
YoY Change		27.83%
SHAREHOLDERS EQUITY
Retained Earnings		-$161.0M
YoY Change		0.3%
Common Stock		$158.8M
YoY Change		0.01%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity		-$2.178M
YoY Change
Total Liabilities & Shareholders Equity		$1.635K
YoY Change		138.34%

Cashflow Statement

Concept	2024 Q4	2024 Q3
OPERATING ACTIVITIES
Net Income		-$122.0K
YoY Change		7.41%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities		-$15.45K
YoY Change		95.08%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		16.41K
YoY Change		106.42%
NET CHANGE
Cash From Operating Activities		-15.45K
Cash From Investing Activities
Cash From Financing Activities		16.41K
Net Change In Cash		960.0
YoY Change		3100.0%
FREE CASH FLOW
Cash From Operating Activities		-$15.45K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Gross Profit GrossProfit		usd
	us-gaap	Gross Profit GrossProfit		usd
CY2024Q3	us-gaap	Revenues Revenues		usd
	us-gaap	Revenues Revenues		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	dei	Entity Central Index Key EntityCentralIndexKey	0001310488
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	000-51074
	dei	Entity Registrant Name EntityRegistrantName	BIOFORCE NANOSCIENCES HOLDINGS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	74-3078125
	dei	Entity Address Address Line1 EntityAddressAddressLine1	2020 General Booth Blvd.
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	29271755	shares
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1635	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	638	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	1635	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	638	usd
CY2024Q3	us-gaap	Assets Assets	1635	usd
CY2023Q4	us-gaap	Assets Assets	638	usd
CY2024Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	6261	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2649	usd
CY2024Q3	us-gaap	Accrued Salaries Current And Noncurrent AccruedSalariesCurrentAndNoncurrent	1913767	usd
CY2023Q4	us-gaap	Accrued Salaries Current And Noncurrent AccruedSalariesCurrentAndNoncurrent	1596517	usd
CY2024Q3	bfnh	Due To Related Parties DueToRelatedParties	260039	usd
CY2023Q4	bfnh	Due To Related Parties DueToRelatedParties	220702	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	2180067	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1819868	usd
	dei	Amendment Flag AmendmentFlag	false
CY2023Q3	us-gaap	Gross Profit GrossProfit		usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
	bfnh	Captial Contributions CaptialContributions		usd
	dei	Entity Address State Or Province EntityAddressStateOrProvince	VA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	23454
	dei	City Area Code CityAreaCode	757
	dei	Local Phone Number LocalPhoneNumber	306-6090
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024Q3	us-gaap	Liabilities Liabilities	2180067	usd
CY2023Q4	us-gaap	Liabilities Liabilities	1819868	usd
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	29271755	shares
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	29272	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	29272	usd
CY2024Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	158789302	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	158781227	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-160997006	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-160629729	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	-2178432	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-1819230	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1635	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	638	usd
CY2024Q3	us-gaap	Compensation Expense Excluding Cost Of Good And Service Sold CompensationExpenseExcludingCostOfGoodAndServiceSold	105750	usd
CY2023Q3	us-gaap	Compensation Expense Excluding Cost Of Good And Service Sold CompensationExpenseExcludingCostOfGoodAndServiceSold	105750	usd
	us-gaap	Compensation Expense Excluding Cost Of Good And Service Sold CompensationExpenseExcludingCostOfGoodAndServiceSold	317250	usd
	us-gaap	Compensation Expense Excluding Cost Of Good And Service Sold CompensationExpenseExcludingCostOfGoodAndServiceSold	317250	usd
CY2024Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	16274	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7857	usd
CY2024Q3	us-gaap	Operating Expenses OperatingExpenses	122024	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	113607	usd
	us-gaap	Operating Expenses OperatingExpenses	367277	usd
	us-gaap	Operating Expenses OperatingExpenses	357543	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-113607	usd
	us-gaap	Net Income Loss NetIncomeLoss	-367277	usd
	us-gaap	Net Income Loss NetIncomeLoss	-357543	usd
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	29271755	shares
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	29271755	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	29271755	shares
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.00
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.00
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.00
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
	us-gaap	Net Income Loss NetIncomeLoss	-367277	usd
	us-gaap	Net Income Loss NetIncomeLoss	-357543	usd
	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	317250	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-46415	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-39616	usd
	bfnh	Captial Contributions CaptialContributions	8075	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	39337	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	39568	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	47412	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	39568	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	997	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-48	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	638	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	734	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1635	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	686	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-1347277	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-130005	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-1477282	usd
CY2023Q2	us-gaap	Profit Loss ProfitLoss	-113931	usd
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q3	us-gaap	Revenues Revenues		usd
	us-gaap	Revenues Revenues		usd
CY2024Q3	us-gaap	Cost Of Revenue CostOfRevenue		usd
CY2023Q3	us-gaap	Cost Of Revenue CostOfRevenue		usd
	us-gaap	Cost Of Revenue CostOfRevenue		usd
	us-gaap	Cost Of Revenue CostOfRevenue		usd
CY2024Q3	us-gaap	Gross Profit GrossProfit		usd
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Unit 230
	dei	Entity Address City Or Town EntityAddressCityOrTown	Virginia Beach
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	900000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	900000000	shares
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	29271755	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	29271755	shares
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	29271755	shares
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	50027	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	40293	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-122024	usd
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	29271755	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	29271755	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	29271755	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	29271755	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	29271755	shares
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.00
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	3612	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	677	usd
	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	317250	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-1591213	usd
CY2023Q3	us-gaap	Profit Loss ProfitLoss	-113607	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-1704820	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-1819230	usd
CY2024Q1	us-gaap	Profit Loss ProfitLoss	-130813	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-1950043	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	75	usd
CY2024Q2	us-gaap	Profit Loss ProfitLoss	-114440	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-2064408	usd
CY2024Q3	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	8000	usd
CY2024Q3	us-gaap	Profit Loss ProfitLoss	-122024	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	-2178432	usd
CY2020Q2	bfnh	Business Acquisition Equity Interests Purchased Number Of Shares BusinessAcquisitionEquityInterestsPurchasedNumberOfShares	100000	shares
CY2020Q2	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	1000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84B_eus-gaap--UseOfEstimates_z3vmcKy2MBwi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_865_zzQXwTESo3s">Use of Estimates</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
	us-gaap	Other Expenses OtherExpenses	39338	usd
	us-gaap	Other Expenses OtherExpenses	39568	usd
CY2024Q3	bfnh	Due To Related Parties DueToRelatedParties	260039	usd
CY2023Q3	bfnh	Due To Related Parties DueToRelatedParties	213664	usd
CY2024Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	100000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	100000000	shares
CY2024Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
	us-gaap	Preferred Stock Conversion Basis PreferredStockConversionBasis	Preferred stock can be converted into 100 shares of common stock, have dividend rights at 100 times common and have voting rights equal to 100 shares of common stock.
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	900000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	900000000	shares
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	5 to 1 reverse split.
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	29271755	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	29271755	shares
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	29271755	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	29271755	shares
	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001091818-24-000134-index-headers.html	Edgar Link	pending
0001091818-24-000134-index.html	Edgar Link	pending
0001091818-24-000134.txt	Edgar Link	pending
0001091818-24-000134-xbrl.zip	Edgar Link	pending
bfnh-20240930.xsd	Edgar Link	pending
bfnh-20240930_cal.xml	Edgar Link	unprocessable
bfnh-20240930_def.xml	Edgar Link	unprocessable
bfnh20240930_10q.htm	Edgar Link	pending
bfnhlogo2019001.jpg	Edgar Link	pending
ex311.htm	Edgar Link	pending
ex312.htm	Edgar Link	pending
ex321.htm	Edgar Link	pending
ex322.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
bfnh20240930_10q_htm.xml	Edgar Link	completed
R18.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
bfnh-20240930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
bfnh-20240930_lab.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BFNH
BIOFORCE NANOSCIENCES HOLDINGS, INC. Stock $bfnh

2024 Q4 Form 10-Q Financial Statement

#000109181824000134 Filed on November 08, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BFNH BIOFORCE NANOSCIENCES HOLDINGS, INC. Stock $bfnh

2024 Q4 Form 10-Q Financial Statement

#000109181824000134 Filed on November 08, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BFNH
BIOFORCE NANOSCIENCES HOLDINGS, INC. Stock $bfnh